Nucleic acid aptamers targeting cell-surface proteins.

Aptamers are chemical antibodies that bind to their targets with high affinity and specificity. These short stretches of nucleic acids are identified using a repetitive in vitro selection and partitioning technology called SELEX (Systematic Evolution of Ligands by EXponential enrichment). Since the emergence of this technology, many modifications and variations have been introduced to enable the selection of specific ligands, even for implausible targets. For membrane protein, the selection scheme can be chosen depending upon the availability of the system, the protein characteristics and the application required. Aptamers have been generated for a significant number of disease-associated membrane proteins and have been shown to have considerable diagnostic and therapeutic importance. In this article, we review the SELEX process used for identification of aptamers that target cell-surface proteins and recapitulate their use as therapeutic and diagnostic reagents.

[1]  L. Gold,et al.  Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. , 1990, Science.

[2]  A. Perkins,et al.  Design and synthesis of mono- and multimeric targeted radiopharmaceuticals based on novel cyclen ligands coupled to anti-MUC1 aptamers for the diagnostic imaging and targeted radiotherapy of cancer. , 2007, Bioconjugate chemistry.

[3]  N. Bander,et al.  Constitutive and antibody-induced internalization of prostate-specific membrane antigen. , 1998, Cancer research.

[4]  Yong Wang,et al.  Cell type–specific delivery of siRNAs with aptamer-siRNA chimeras , 2006, Nature Biotechnology.

[5]  Michael Famulok,et al.  Enrichment of cell-targeting and population-specific aptamers by fluorescence-activated cell sorting. , 2008, Angewandte Chemie.

[6]  M Yarus,et al.  Diversity of oligonucleotide functions. , 1995, Annual review of biochemistry.

[7]  J. Aronowski,et al.  Water soluble RNA based antagonist of AMPA receptors , 2007, Neuropharmacology.

[8]  C. Zhang,et al.  Inter-RNA interaction of phage phi29 pRNA to form a hexameric complex for viral DNA transportation. , 1998, Molecular cell.

[9]  Sheela M. Waugh,et al.  2′-Fluoropyrimidine RNA-based Aptamers to the 165-Amino Acid Form of Vascular Endothelial Growth Factor (VEGF165) , 1998, The Journal of Biological Chemistry.

[10]  S. Dupuis,et al.  Telomere elongation by hnRNP A1 and a derivative that interacts with telomeric repeats and telomerase , 1998, Nature Genetics.

[11]  Ying-Fon Chang,et al.  Tenascin-C Aptamers Are Generated Using Tumor Cells and Purified Protein* , 2001, The Journal of Biological Chemistry.

[12]  Peixuan Guo,et al.  Construction of phi29 DNA-packaging RNA monomers, dimers, and trimers with variable sizes and shapes as potential parts for nanodevices. , 2003, Journal of nanoscience and nanotechnology.

[13]  Peixuan Guo,et al.  Computer Modeling of Three-dimensional Structure of DNA-packaging RNA (pRNA) Monomer, Dimer, and Hexamer of Phi29 DNA Packaging Motor* , 2002, The Journal of Biological Chemistry.

[14]  A. Barfod,et al.  In vitro selection of RNA aptamers against a conserved region of the Plasmodium falciparum erythrocyte membrane protein 1 , 2009, Parasitology Research.

[15]  D. Shangguan,et al.  Aptamer Directly Evolved from Live Cells Recognizes Membrane Bound Immunoglobin Heavy Mu Chain in Burkitt's Lymphoma Cells*S , 2007, Molecular & Cellular Proteomics.

[16]  L. Gold,et al.  Post-SELEX combinatorial optimization of aptamers. , 1997, Bioorganic & medicinal chemistry.

[17]  Joshua E. Smith,et al.  Aptamer-conjugated nanoparticles for the collection and detection of multiple cancer cells. , 2007, Analytical chemistry.

[18]  A. Bergamaschi,et al.  hnRNP A1 Nucleocytoplasmic Shuttling Activity Is Required for Normal Myelopoiesis and BCR/ABL Leukemogenesis , 2002, Molecular and Cellular Biology.

[19]  Xiao-lian Zhang,et al.  CS-SELEX Generates High-Affinity ssDNA Aptamers as Molecular Probes for Hepatitis C Virus Envelope Glycoprotein E2 , 2009, PloS one.

[20]  J C Cox,et al.  Automated selection of anti-protein aptamers. , 2001, Bioorganic & medicinal chemistry.

[21]  H. Schluesener,et al.  Systematic Evolution of a DNA Aptamer Binding to Rat Brain Tumor Microvessels , 2001, The Journal of Biological Chemistry.

[22]  S. Gopinath.  Methods developed for SELEX , 2006, Analytical and bioanalytical chemistry.

[23]  B. Hicke,et al.  Escort aptamers: a delivery service for diagnosis and therapy. , 2000, The Journal of clinical investigation.

[24]  Youli Zu,et al.  Combination of an aptamer probe to CD4 and antibodies for multicolored cell phenotyping. , 2010, American journal of clinical pathology.

[25]  Hui Chen,et al.  Molecular recognition of acute myeloid leukemia using aptamers , 2008, Leukemia.

[26]  Weihong Tan,et al.  Molecular Recognition of Small‐Cell Lung Cancer Cells Using Aptamers , 2008, ChemMedChem.

[27]  J. Yates,et al.  The application of mass spectrometry to membrane proteomics , 2003, Nature Biotechnology.

[28]  Soyoun Kim,et al.  Patents on SELEX and therapeutic aptamers. , 2008, Recent patents on DNA & gene sequences.

[29]  Yi Lu,et al.  Reversible cell-specific drug delivery with aptamer-functionalized liposomes. , 2009, Angewandte Chemie.

[30]  B. Shen,et al.  Single-stranded DNA aptamers that bind differentiated but not parental cells: subtractive systematic evolution of ligands by exponential enrichment. , 2003, Journal of biotechnology.

[31]  Sunjoo Jeong,et al.  Use of RNA aptamers for the modulation of cancer cell signaling. , 2009, Methods in molecular biology.

[32]  C. Sanders,et al.  Misfolding of membrane proteins in health and disease: the lady or the tiger? , 2000, Current opinion in structural biology.

[33]  Sergey N Krylov,et al.  Aptamer-facilitated biomarker discovery (AptaBiD). , 2008, Journal of the American Chemical Society.

[34]  J. Wills,et al.  Isolation of virus-neutralizing RNAs from a large pool of random sequences. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[35]  C. Zhang,et al.  Sequence requirement for hand-in-hand interaction in formation of RNA dimers and hexamers to gear phi29 DNA translocation motor. , 1999, RNA.

[36]  J. Gariépy,et al.  Phototoxic aptamers selectively enter and kill epithelial cancer cells , 2008, Nucleic acids research.

[37]  Peixuan Guo.  The emerging field of RNA nanotechnology. , 2010, Nature nanotechnology.

[38]  L. Gold,et al.  A tenascin-C aptamer identified by tumor cell SELEX: Systematic evolution of ligands by exponential enrichment , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[39]  Peixuan Guo,et al.  Controllable self-assembly of nanoparticles for specific delivery of multiple therapeutic molecules to cancer cells using RNA nanotechnology. , 2005, Nano letters.

[40]  B. Sullenger,et al.  RNA aptamers as reversible antagonists of coagulation factor IXa , 2002, Nature.

[41]  Weihong Tan,et al.  Cell-specific aptamer probes for membrane protein elucidation in cancer cells. , 2008, Journal of proteome research.

[42]  Yong-Min Huh,et al.  Isolation of RNA Aptamers Targeting HER -2-overexpressing Breast Cancer Cells Using Cell-SELEX , 2009 .

[43]  Yoshikazu Nakamura,et al.  Selection of RNA aptamers against recombinant transforming growth factor-beta type III receptor displayed on cell surface. , 2006, Biochimie.

[44]  Omid C Farokhzad,et al.  Co‐Delivery of Hydrophobic and Hydrophilic Drugs from Nanoparticle–Aptamer Bioconjugates , 2007, ChemMedChem.

[45]  L. Gold,et al.  High affinity ligands from in vitro selection: complex targets. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[46]  P. Burgstaller,et al.  Biostable aptamers with antagonistic properties to the neuropeptide nociceptin/orphanin FQ. , 2004, RNA.

[47]  Robert Langer,et al.  Nanotechnology and Aptamers: Applications in Drug Delivery , 2022 .

[48]  D. S. Coffey,et al.  Identification and characterization of nuclease-stabilized RNA molecules that bind human prostate cancer cells via the prostate-specific membrane antigen. , 2002, Cancer research.

[49]  G. Clawson,et al.  Minimal primer and primer-free SELEX protocols for selection of aptamers from random DNA libraries. , 2008, BioTechniques.

[50]  A. Perkins,et al.  Anti-MUC1 aptamers: radiolabelling with (99m)Tc and biodistribution in MCF-7 tumour-bearing mice. , 2009, Nuclear medicine and biology.

[51]  J. Richie,et al.  Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[52]  Akihiko Kondo,et al.  Selection of DNA aptamers using atomic force microscopy , 2009, Nucleic acids research.

[53]  Charles R Sanders,et al.  Disease-related misassembly of membrane proteins. , 2004, Annual review of biophysics and biomolecular structure.

[54]  G. G. Stokes.  "J." , 1890, The New Yale Book of Quotations.

[55]  Robert Langer,et al.  An aptamer-doxorubicin physical conjugate as a novel targeted drug-delivery platform. , 2006, Angewandte Chemie.

[56]  Shu-Jyuan Yang,et al.  Aptamer-based tumor-targeted drug delivery for photodynamic therapy. , 2010, ACS nano.

[57]  Anthony D. Keefe,et al.  Aptamers as therapeutics , 2010, Nature Reviews Drug Discovery.

[58]  A. Barclay,et al.  Cutting edge: novel RNA ligands able to bind CD4 antigen and inhibit CD4+ T lymphocyte function. , 1998, Journal of immunology.

[59]  G. Blobe,et al.  Cell-surface co-receptors: emerging roles in signaling and human disease. , 2005, Trends in biochemical sciences.

[60]  E. Kokkoli,et al.  Peptide- and aptamer-functionalized nanovectors for targeted delivery of therapeutics. , 2009, Journal of biomechanical engineering.

[61]  M. Willis,et al.  Diagnostic potential of PhotoSELEX-evolved ssDNA aptamers. , 2000, Journal of biotechnology.

[62]  D. Shangguan,et al.  Aptamers evolved from live cells as effective molecular probes for cancer study , 2006, Proceedings of the National Academy of Sciences.

[63]  K. Thompson,et al.  Pharmacokinetics and Biodistribution of Novel Aptamer Compositions , 2004, Pharmaceutical Research.

[64]  B. Sullenger,et al.  Multivalent RNA aptamers that inhibit CTLA-4 and enhance tumor immunity. , 2003, Cancer research.

[65]  B. Sullenger,et al.  In vivo selection of tumor-targeting RNA motifs , 2009, Nature chemical biology.

[66]  Dong-Ki Lee,et al.  Selection and elution of aptamers using nanoporous sol-gel arrays with integrated microheaters. , 2009, Lab on a chip.

[67]  Andrew D Ellington,et al.  Aptamer:toxin conjugates that specifically target prostate tumor cells. , 2006, Cancer research.

[68]  Ying Li,et al.  Aptamers evolved from cultured cancer cells reveal molecular differences of cancer cells in patient samples. , 2007, Clinical chemistry.

[69]  S. Stavchansky,et al.  Pharmacokinetics and Biodistribution of a Nucleotide-Based Thrombin Inhibitor in Rats , 1998, Pharmaceutical Research.

[70]  J. Szostak,et al.  In vitro selection of RNA molecules that bind specific ligands , 1990, Nature.

[71]  Anton P. McCaffrey,et al.  Systemic administration of optimized aptamer-siRNA chimeras promotes regression of PSMA-expressing tumors , 2009, Nature Biotechnology.

[72]  M. Olive,et al.  hnRNP A1 Recruited to an Exon In Vivo Can Function as an Exon Splicing Silencer , 1999, Molecular and Cellular Biology.

[73]  S. Gill,et al.  Detection and plasma pharmacokinetics of an anti-vascular endothelial growth factor oligonucleotide-aptamer (NX1838) in rhesus monkeys. , 1999, Journal of chromatography. B, Biomedical sciences and applications.

[74]  S. Akbarian,et al.  Editing for an AMPA receptor subunit RNA in prefrontal cortex and striatum in Alzheimer's disease, Huntington's disease and schizophrenia , 1995, Brain Research.

[75]  Bertrand Tavitian,et al.  Neutralizing Aptamers from Whole-Cell SELEX Inhibit the RET Receptor Tyrosine Kinase , 2005, PLoS biology.

[76]  Gerhard Ziemer,et al.  Streptavidin-coated magnetic beads for DNA strand separation implicate a multitude of problems during cell-SELEX. , 2009, Oligonucleotides.

[77]  P. Andrews,et al.  The effect of detergents on proteins analyzed by electrospray ionization. , 1996, Methods in molecular biology.

[78]  L. Jaeger,et al.  The architectonics of programmable RNA and DNA nanostructures. , 2006, Current opinion in structural biology.

[79]  M. Molloy,et al.  Membrane proteins and proteomics: Un amour impossible? , 2000, Electrophoresis.

[80]  S. Klußmann,et al.  The aptamer handbook : functional oligonucleotides and their applications , 2006 .

[81]  James O McNamara,et al.  Targeted inhibition of αvβ3 integrin with an RNA aptamer impairs endothelial cell growth and survival , 2005 .

[82]  N. Windbichler,et al.  Isolation of specific RNA-binding proteins using the streptomycin-binding RNA aptamer , 2006, Nature Protocols.

[83]  J. Clifton,et al.  Membrane proteins as diagnostic biomarkers and targets for new therapies. , 2008, Current opinion in molecular therapeutics.

[84]  B. Sakmann,et al.  A family of AMPA-selective glutamate receptors. , 1990, Science.

[85]  T. Zhang,et al.  Liposome-anchored vascular endothelial growth factor aptamers. , 1998, Bioconjugate chemistry.

[86]  Renee K Mosing,et al.  Isolating aptamers using capillary electrophoresis-SELEX (CE-SELEX). , 2009, Methods in molecular biology.

[87]  R. Landgraf,et al.  Inhibition of heregulin signaling by an aptamer that preferentially binds to the oligomeric form of human epidermal growth factor receptor-3 , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[88]  M. Avci-Adali,et al.  Upgrading SELEX Technology by Using Lambda Exonuclease Digestion for Single-Stranded DNA Generation , 2009, Molecules.

[89]  John J Rossi,et al.  Novel dual inhibitory function aptamer-siRNA delivery system for HIV-1 therapy. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

[90]  F. Major,et al.  Function of hexameric RNA in packaging of bacteriophage phi 29 DNA in vitro. , 1998, Molecular cell.

[91]  Mark E. Davis,et al.  Nanoparticle therapeutics: an emerging treatment modality for cancer , 2008, Nature Reviews Drug Discovery.

[92]  Weihong Tan,et al.  Identification of liver cancer-specific aptamers using whole live cells. , 2008, Analytical chemistry.

[93]  H. Ulrich,et al.  Development of the anti-VEGF aptamer to a therapeutic agent for clinical ophthalmology , 2007, Clinical ophthalmology.

[94]  Hua Shi,et al.  RNA aptamers selected against the GluR2 glutamate receptor channel. , 2007, Biochemistry.

[95]  N. Janjić,et al.  Nuclease-resistant nucleic acid ligands to vascular permeability factor/vascular endothelial growth factor. , 1995, Chemistry & biology.

[96]  Luigi Martino,et al.  Stability and binding properties of a modified thrombin binding aptamer. , 2008, Biophysical journal.

[97]  A. Varki,et al.  DNA aptamers block L-selectin function in vivo. Inhibition of human lymphocyte trafficking in SCID mice. , 1996, The Journal of clinical investigation.

[98]  Ying-Fon Chang,et al.  Tumor targeting by an aptamer. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[99]  Bertrand Tavitian,et al.  Comparison of different strategies to select aptamers against a transmembrane protein target. , 2006, Oligonucleotides.

[100]  Robert Langer,et al.  Superparamagnetic Iron Oxide Nanoparticle-Aptamer Bioconjugates for Combined Prostate Cancer Imaging and Therapy , 2011 .

[101]  Jie Li,et al.  Identification of an aptamer targeting hnRNP A1 by tissue slide‐based SELEX , 2009, The Journal of pathology.

[102]  F. Ducongé,et al.  Aptamers against extracellular targets for in vivo applications. , 2005, Biochimie.

[103]  M E Eldefrawi,et al.  In vitro selection of RNA molecules that displace cocaine from the membrane-bound nicotinic acetylcholine receptor. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[104]  A. Barabasi,et al.  Drug—target network , 2007, Nature Biotechnology.

[105]  Tadashi Mori,et al.  RNA aptamers selected against the receptor activator of NF-kappaB acquire general affinity to proteins of the tumor necrosis factor receptor family. , 2004, Nucleic acids research.

[106]  J. Behravan,et al.  Targeted delivery of daunorubicin to T-cell acute lymphoblastic leukemia by aptamer , 2010, Journal of drug targeting.

[107]  Robert Langer,et al.  Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA–PEG nanoparticles , 2008, Proceedings of the National Academy of Sciences.

[108]  Weihong Tan,et al.  Mapping receptor density on live cells by using fluorescence correlation spectroscopy. , 2009, Chemistry.

[109]  S. Rees,et al.  Generation of RNA aptamers to the G-protein-coupled receptor for neurotensin, NTS-1. , 2002, Analytical biochemistry.

[110]  Sangjin Park,et al.  Drug-loaded superparamagnetic iron oxide nanoparticles for combined cancer imaging and therapy in vivo. , 2008, Angewandte Chemie.

[111]  RNA nanotechnology: inspired by DNA. , 2010, Nature nanotechnology.

[112]  George Georgiou,et al.  Automated selection of aptamers against protein targets translated in vitro: from gene to aptamer. , 2002, Nucleic acids research.

[113]  F. Ducongé,et al.  An Autocrine Loop Involving Ret and Glial Cell–Derived Neurotrophic Factor Mediates Retinoic Acid–Induced Neuroblastoma Cell Differentiation , 2006, Molecular Cancer Research.

[114]  Omid C. Farokhzad,et al.  Nanoparticle-Aptamer Bioconjugates , 2004, Cancer Research.

[115]  John J. Rossi,et al.  Selection, characterization and application of new RNA HIV gp 120 aptamers for facile delivery of Dicer substrate siRNAs into HIV infected cells , 2009, Nucleic acids research.

[116]  H. Ulrich,et al.  Selection of 2′-Fluoro-modified RNA Aptamers for Alleviation of Cocaine and MK-801Inhibition of the Nicotinic Acetylcholine Receptor , 2004, The Journal of Membrane Biology.

[117]  R. Dingledine,et al.  The glutamate receptor ion channels. , 1999, Pharmacological reviews.

[118]  Robert Langer,et al.  Quantum dot-aptamer conjugates for synchronous cancer imaging, therapy, and sensing of drug delivery based on bi-fluorescence resonance energy transfer. , 2007, Nano letters.

[119]  Miss A.O. Penney.  (b) , 1974, The New Yale Book of Quotations.

[120]  C. Mao,et al.  Bottom-up Assembly of RNA Arrays and Superstructures as Potential Parts in Nanotechnology. , 2004, Nano letters.

[121]  Andrew D. Ellington,et al.  Aptamer mediated siRNA delivery , 2006, Nucleic acids research.

[122]  Peixuan Guo,et al.  Specific delivery of therapeutic RNAs to cancer cells via the dimerization mechanism of phi29 motor pRNA. , 2005, Human gene therapy.